Neumora Therapeutics, Inc. cotiza a 0.44 USD y tiene una capitalización bursátil de $82M. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases in the United States. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist,…
| Periodo | 2026-08 | 2026-08 | 2026-05 | 2026-03 |
|---|---|---|---|---|
| Real | $-0.23 | — | $-0.30 | $-0.35 |
| Estimado | $-0.24 | $-0.24 | $-0.31 | $-0.33 |
| Sorpresa | +4.2% | — | +3.2% | -6.1% |
| Métrica | NMRA | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | — | 57.0% | — |
| Operating Margin | — | -38.6% | — |
| Net Margin | — | -33.6% | — |
| FCF Margin | — | -13.9% | — |
| ROE | -228.1% | -40.4% | -187.7% |
| ROA | -124.0% | -32.0% | -92.0% |
| Current Ratio | 5.87 | 2.84 | +3.03 |
| Debt / Equity | 0.52 | 0.28 | +0.24 |